Pharmaco-virological outcomes and genotypic resistance profiles among children and adolescents receiving a DTG-based regimen in Togo
| dc.rights.license | open | en_US |
| dc.contributor.author | KONU, Yao Rodion | |
| dc.contributor.author | TAKASSI, Elom | |
| dc.contributor.author | PEYTAVIN, Gilles | |
| dc.contributor.author | DAPAM, Nina | |
| dc.contributor.author | DAMOND, Florence | |
| dc.contributor.author | OUMAROU, Wone Adama | |
| dc.contributor.author | ZAIDI, Meryem | |
| dc.contributor.author | FRANCO-YUSTI, Anna-Maria | |
| dc.contributor.author | DAGNRA, Claver A. | |
| dc.contributor.author | LE HINGRAT, Quentin | |
| dc.contributor.author | COPPEE, Romain | |
| dc.contributor.author | DESCAMPS, Diane | |
| dc.contributor.author | DIALLO, Fatoumata Binta Tidiane | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| hal.structure.identifier | Global Health in the Global South [GHiGS] | |
| dc.contributor.author | EKOUEVI, Didier Koumavi | |
| dc.contributor.author | CHARPENTIER, Charlotte | |
| dc.date.accessioned | 2024-08-21T12:19:25Z | |
| dc.date.available | 2024-08-21T12:19:25Z | |
| dc.date.issued | 2024-05-15 | |
| dc.identifier.issn | 1537-6591 | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/201234 | |
| dc.description.abstractEn | Background. Few data are available on the real-world efficacy of receiving tenofovir-lamivudine-dolutegravir (-DTG) as human immunodeficiencyvirus (HIV) treatment, particularly among young people in West Africa. Here, we evaluated pharmaco-virological outcomes and resistance profiles among Togolese children and adolescents. Methods. A cross-sectional study was conducted in Lom & eacute;, Togo, enrolling antiretroviral-treated people with HIV aged from 18 months to 24 years. Plasma HIV-1 viral load and antiretroviral concentrations were measured. Next-generation sequencing of protease, reverse transcriptase (RT), and integrase was performed on all samples with viral loads >200 copies/mL. Drug resistance mutations (DRMs) were identified and interpreted using the ANRS-MIE algorithm. Results. 264 participants were enrolled (median age, 17 years); 226 received a DTG-based regimen for a median of 20.5 months. Among them, there was virological suppression at the 200-copies/mL threshold in 80.0% of the participants. Plasma DTG concentrations were adequate (ie, >640 ng/mL), suboptimal, and below the limit of quantification in 74.1%, 6.7%, and 19.2% of participants receiving DTG, respectively. Overall, viruses resistant to any of nucleoside RT inhibitors, non-NRTIs, and protease inhibitors were found in 52%, 66%, and 1.6% of participants, respectively. A major integrase inhibitor DRM was observed in 9.4% (n = 3/32; R263K, E138A-G140A-Q148R, and N155H) of participants with a viral load >200 copies/mL. Conclusions. These first findings in a large series of adolescents in a low-income country showed a good virological response of 80% and the presence of an integrase DRM in 9.4% of virological failures, supporting the need to monitor DTG drug resistance to reduce the risk of resistance acquisition. | |
| dc.language.iso | EN | en_US |
| dc.subject.en | HIV | |
| dc.subject.en | Togo | |
| dc.subject.en | Children/adolescents | |
| dc.subject.en | Concentrations | |
| dc.subject.en | Dolutegravir | |
| dc.subject.en | Resistance | |
| dc.title.en | Pharmaco-virological outcomes and genotypic resistance profiles among children and adolescents receiving a DTG-based regimen in Togo | |
| dc.title.alternative | Clin Infect Dis | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1093/cid/ciae278 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 38748464 | en_US |
| bordeaux.journal | Clinical Infectious Diseases | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | INSERM | en_US |
| bordeaux.team | GHIGS_BPH | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| bordeaux.identifier.funderID | Institut de Recherche pour le Développement | en_US |
| bordeaux.identifier.funderID | World Health Organization | en_US |
| bordeaux.identifier.funderID | Agence Nationale de Recherches sur le Sida et les Hépatites Virales | en_US |
| hal.identifier | hal-04674542 | |
| hal.version | 1 | |
| hal.date.transferred | 2024-08-21T12:19:27Z | |
| hal.popular | non | en_US |
| hal.audience | Internationale | en_US |
| hal.export | true | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Clinical%20Infectious%20Diseases&rft.date=2024-05-15&rft.eissn=1537-6591&rft.issn=1537-6591&rft.au=KONU,%20Yao%20Rodion&TAKASSI,%20Elom&PEYTAVIN,%20Gilles&DAPAM,%20Nina&DAMOND,%20Florence&rft.genre=article |
Files in this item
| Files | Size | Format | View |
|---|---|---|---|
|
There are no files associated with this item. |
|||